Abstract
In the last decade several attempts have been made to achieve the goal of cardiac regeneration after myocardial infarction. To date, two cell types have completed phase-III clinical trials: Skeletal Myoblasts and Bone-Marrow Mononuclear Cells (BM-MNCs). In the first case, all benefits have been limited by an increased risk of arrhythmia. In the case of BM-cells, most studies showed a significant, although limited, advantage in the cell-treated group. This may be due to the choice of the wrong BM cell type: other candidates would be e.g. CD34+ HSCs, or non-hematopoietic Mesenchymal Stem Cells. After positive results from the experimental studies, phase I/II clinical trials are currently on-going for both.
Ideally, the best cell to use to regenerate the heart would be a precursor of all cardiac lineages; until the isolation and expansion of Cardiac Stem Cells (CSCs), such a cell was thought to exist only during embryogenesis. Using CSCs researchers managed to generate electrically-coupled contractile tissue within the infarct of animal models. Still, some doubts persist over the possibility to translate such results in real-life patients.
Another approach, therefore, involves the use of induced Pluripotent Stem Cells (iPS) obtained from fibroblasts after genetic reprogramming. This new type of cell would combine the pluripotency of embryonal stem cells with the advantages of an autologous use. Nevertheless, iPS cells form teratomas, and their effective differentiation in vivo is largely unknown.
This review will critically compare the data from the Literature concerning cell therapy after myocardial infarction. Can we name the best cell?
Keywords: Adult stem cells, cardiac regeneration, cell therapy, bone marrow, mesenchymal stem cells, cardiac stem cells, induced pluripotent stem cells, acute myocardial infarction
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Cell Therapy for Cardiac Regeneration after Myocardial Infarct: Which Cell is the Best?
Volume: 8 Issue: 4
Author(s): Federico Mosna, Francesco Annunziato, Giovanni Pizzolo and Mauro Krampera
Affiliation:
Keywords: Adult stem cells, cardiac regeneration, cell therapy, bone marrow, mesenchymal stem cells, cardiac stem cells, induced pluripotent stem cells, acute myocardial infarction
Abstract: In the last decade several attempts have been made to achieve the goal of cardiac regeneration after myocardial infarction. To date, two cell types have completed phase-III clinical trials: Skeletal Myoblasts and Bone-Marrow Mononuclear Cells (BM-MNCs). In the first case, all benefits have been limited by an increased risk of arrhythmia. In the case of BM-cells, most studies showed a significant, although limited, advantage in the cell-treated group. This may be due to the choice of the wrong BM cell type: other candidates would be e.g. CD34+ HSCs, or non-hematopoietic Mesenchymal Stem Cells. After positive results from the experimental studies, phase I/II clinical trials are currently on-going for both.
Ideally, the best cell to use to regenerate the heart would be a precursor of all cardiac lineages; until the isolation and expansion of Cardiac Stem Cells (CSCs), such a cell was thought to exist only during embryogenesis. Using CSCs researchers managed to generate electrically-coupled contractile tissue within the infarct of animal models. Still, some doubts persist over the possibility to translate such results in real-life patients.
Another approach, therefore, involves the use of induced Pluripotent Stem Cells (iPS) obtained from fibroblasts after genetic reprogramming. This new type of cell would combine the pluripotency of embryonal stem cells with the advantages of an autologous use. Nevertheless, iPS cells form teratomas, and their effective differentiation in vivo is largely unknown.
This review will critically compare the data from the Literature concerning cell therapy after myocardial infarction. Can we name the best cell?
Export Options
About this article
Cite this article as:
Mosna Federico, Annunziato Francesco, Pizzolo Giovanni and Krampera Mauro, Cell Therapy for Cardiac Regeneration after Myocardial Infarct: Which Cell is the Best?, Cardiovascular & Hematological Agents in Medicinal Chemistry 2010; 8 (4) . https://dx.doi.org/10.2174/187152510792481216
DOI https://dx.doi.org/10.2174/187152510792481216 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry Pharmacotherapy in Pedatric PTSD: A Developmentally-Focused Review of the Evidence
Current Psychopharmacology Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update
CNS & Neurological Disorders - Drug Targets Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Blood Pressure Measurement: Lessons Learned from Our Ancestors
Current Pharmaceutical Design Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Antitumor Titanium Compounds
Mini-Reviews in Medicinal Chemistry Mechanism of Local Anesthetic Drug Action on Voltage-Gated Sodium Channels
Current Pharmaceutical Design The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets TakoTsubo Cardiomyopathy A Short Review
Current Cardiology Reviews Introduction (Transient Receptor Potential TRP Channels as Therapeutic Drug Targets: Next Round!)
Current Topics in Medicinal Chemistry Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews